Locus 142: COMT (22q11.21)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs4680 |
X-11593--O-methylascorbate* |
A/G |
7344 |
0.51 |
-0.049 (0.002) |
4.66·10-178 |
show |
| rs4680 |
X-01911 |
A/G |
6000 |
0.51 |
-0.044 (0.006) |
1.31·10-13 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs4680 |
| Chromosomal location | Chr22: 18,331,271 (22q11.21) |
| Gene (distance) | COMT (0) |
| Predicted causal gene | COMT |
| Gene/protein classification | drug target, metabolic enzyme |
| Metabolite (Pathway) | X-11593--O-methylascorbate* (Ascorbate and aldarate metabolism; Cofactors and vitamins) |
| Biochemical locus-metabolite relationship | COMT encodes catechol-O-methyltransferase, which can methylate ascorbic acid to form O-methylascorbate [7129800]. X-11593 was experimentally identified to be O-methylascorbate [23093944] |
| eQTL associations | ZDHHC8 (L) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information |
| Complex trait associations | - |
| Known metabolite associations | X-11593,X-01911 [23093944] |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL2023 |
| Drug information |
Substrates: Levodopa; Inhibitors: Entacapone, Tolcapone
(more details...) |
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

